Ragnhild Sørum Falk

Ragnhild Sørum Falk

Auto-generated profile, based on publicly available information

Ragnhild Sørum Falk

Research Support Services, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
HOHege O. Ohnstad
Hege O. Ohnstad
EBElin Borgen
Elin Borgen
RFRagnhild S. Falk
Ragnhild S. Falk
TLTonje Lien
Tonje Lien
MAMarit Aaserud
Marit Aaserud
BNBjørn Naume
Bjørn Naume
The aim of this study was to investigate the prognostic value of the PAM50 intrinsic subtypes and risk of recurrence (ROR) score in patients with early breast cancer and long-term follow-up. A special focus was placed on hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) pN0 patients not treated with chemotherapy. Patients with early breast cancer (n = 653) enrolled in the observational Oslo1 study (1995–1998) were followed for distant recurrence and breast cancer death. Clinicopathological parameters were collected from hospital records. The primary tumors were analyzed using the Prosigna® PAM50 assay to determine the prognostic value of the intrinsic subtypes and ROR score in comparison with pathological characteristics. The primary endpoints were distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS). Of 653 tumors, 52.2% were classified as luminal A, 26.5% as luminal B, 10.6% as HER2-enriched, and 10.7% as basal-like. Among the HR+/HER2− patients (n = 476), 37.8% were categorized as low risk by ROR score, 22.7% as intermediate risk, and 39.5% as high risk. Median follow-up durations for BCSS and DDFS were 16.6 and 7.1 years, respectively. Multivariate analysis showed that intrinsic subtypes (all patients) and ROR risk classification (HR+/HER2− patients) yielded strong prognostic information. Among the HR+/HER2− pN0 patients with no adjuvant treatment (n = 231), 53.7% of patients had a low ROR, and their prognosis at 15 years was excellent (15-year BCSS 96.3%). Patients with intermediate risk had reduced survival compared with those with low risk (p = 0.005). In contrast, no difference in survival between the low- and intermediate-risk groups was seen for HR+/HER2− pN0 patients who received tamoxifen only. Ki-67 protein, grade, and ROR score were analyzed in the unselected, untreated pT1pN0 HR+/HER2− population (n = 171). In multivariate analysis, ROR score outperformed both Ki-67 and grade. Furthermore, 55% of patients who according to the PREDICT tool ( http://www.predict.nhs.uk/ ) would be considered chemotherapy candidates were ROR low risk (33%) or luminal A ROR intermediate risk (22%). The PAM50 intrinsic subtype classification and ROR score improve classification of patients with breast cancer into prognostic groups, allowing for a more precise identification of future recurrence risk and providing an improved basis for adjuvant treatment decisions. Node-negative patients with low ROR scores had an excellent outcome at 15 years even in the absence of adjuvant therapy.

19 June 2021 in Quality of Life Research
Verified
Journal Article
Open access
PDF file
CACecilie Delphin Amdal
Cecilie Delphin Amdal
MPMadeline Pe
Madeline Pe
RFRagnhild Sørum Falk
Ragnhild Sørum Falk
CPClaire Piccinin
Claire Piccinin
ABAndrew Bottomley
Andrew Bottomley
KBKristin Bjordal
Kristin Bjordal
Purpose: This systematic review was performed to identify all relevant health-related quality of life (HRQoL) issues associated with COVID-19. Methods: A systematic literature search was undertaken in April 2020. In four teams of three reviewers each, all abstracts were independently reviewed for inclusion by two reviewers. Using a pre-defined checklist of 93 criteria for each publication, data extraction was performed independently by two reviewers and subsequently compared and discussed. If necessary, a third reviewer resolved any discrepancies. The search was updated in February 2021 to retrieve new publications on HRQoL issues including issues related to the long-term consequences of COVID-19. Results: The search in April 2020 identified 3342 potentially relevant publications, and 339 publications were selected for full-text review and data extraction. We identified 75 distinct symptoms and other HRQoL issues categorized into 12 thematic areas; from general symptoms such as fever, myalgia, and fatigue, to neurological and psychological issues. The updated search revealed three extra issues experienced during active disease and long-term problems with fatigue, psychological issues and impaired cognitive function. Conclusion: This first comprehensive systematic review provides a detailed overview of the wide range of HRQoL issues experienced by patients with COVID-19 throughout the course of the disease. It demonstrates the devastating impact of the disease and provides critically important information for clinicians, to enable them to better recognize the disease and to provide knowledge important for treatment and follow-up. The results provided the foundation for the international development of a COVID-19 specific patient-reported HRQoL questionnaire.

17 December 2015 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SHSven-Petter Haugvik
Sven-Petter Haugvik
EJEva Tiensuu Janson
Eva Tiensuu Janson
POPia Osterlund
Pia Osterlund
SLSeppo W. Langer
Seppo W. Langer
RFRagnhild Sørum Falk
Ragnhild Sørum Falk
HSHalfdan Sorbye
Halfdan Sorbye

1 December 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BNBjørn Naume
Bjørn Naume
MSMarit Synnestvedt
Marit Synnestvedt
RFRagnhild Sørum Falk
Ragnhild Sørum Falk
GWGro Wiedswang
Gro Wiedswang
KWKjetil Weyde
Kjetil Weyde
EBElin Borgen
Elin Borgen
Purpose: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) predicts survival in early breast cancer. This study explores the use of DTCs for identification of patients insufficiently treated with adjuvant therapy so they can be offered secondary adjuvant treatment and the subsequent surrogate marker potential of DTCs for outcome determination. Patients and Methods: Patients with early breast cancer who had completed six cycles of adjuvant fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy underwent BM aspiration 2 to 3 months (BM1) and 8 to 9 months (BM2) after FEC. Presence of DTCs in BM was determined by immunocytochemistry using pan-cytokeratin monoclonal antibodies. If one or more DTCs were present at BM2, six cycles of docetaxel (100 mg/m2, once every 3 weeks) were administered, followed by DTC analysis 1 and 13 months after the last docetaxel infusion (after treatment). Cox regression analysis was used to evaluate disease-free interval (DFI). Results: Of 1,066 patients with a DTC result at BM2 and available follow-up information (median follow-up, 71.9 months from the time of BM2), 7.2% were DTC positive. Of 72 docetaxel-treated patients analyzed for DTCs after treatment, 15 (20.8%) had persistent DTCs. Patients with remaining DTCs had markedly reduced DFI (46.7% experienced relapse) compared with patients with no DTCs after treatment (adjusted hazard ratio, 7.58; 95% CI, 2.3 to 24.7). The docetaxel-treated patients with no DTCs after treatment had comparable DFI (8.8% experienced relapse) compared with those with no DTCs both at BM1 and BM2 (12.7% experienced relapse; P = .377, log-rank test). Conclusion: DTC status identifies high-risk patients after FEC chemotherapy, and DTC monitoring status after secondary treatment with docetaxel correlated strongly with survival. This emphasizes the potential for DTC analysis as a surrogate marker for adjuvant treatment effect in breast cancer.

1 December 2017 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
GHGry S. Haaland
Gry S. Haaland
RFRagnhild S. Falk
Ragnhild S. Falk
OSOddbjørn Straume
Oddbjørn Straume
JLJames B. Lorens
James B. Lorens
Warfarin sodium is the most used anticoagulant worldwide and is prescribed to 5% to 10% of the adult population in Western countries1 for a range of indications, including atrial fibrillation, prosthetic heart valves, and venous thromboembolism.2,3 The antitumor potential of warfarin is demonstrated in different experimental cancer model systems.4-7 Previous epidemiological studies differ regarding the association between warfarin and cancer, with one suggesting a specific association with urogenital cancers8 and another indicating no association with cancer incidence.9 A clearly defined molecular mechanism of how vitamin K antagonism affects cancer development and a population-based cohort study are needed to resolve this controversy.

1 April 2018 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
IRIngrid Roscher
Ingrid Roscher
RFRagnhild S. Falk
Ragnhild S. Falk
LVLinda Vos
Linda Vos
OCOle P. F. Clausen
Ole P. F. Clausen
PHPer Helsing
Per Helsing
TRTrude E. Robsahm
Trude E. Robsahm
Cutaneous squamous cell carcinoma (cSCC) is increasing in incidence and is now ranked as the second most common skin cancer world-wide.1 When excised surgically with free margins, the prognosis is mostly good,2 but it is poor if metastasis has occurred.3- 5 Several staging systems for cSCC have been developed to predict patients’ risk of metastasis and to individualize treatment and the follow-up schedule (Figure 1).6- 9 In 2011, the American Joint Committee on Cancer (AJCC) published the 7th edition of its staging system (AJCC 7),6 which is based on tumor diameter and several risk features, including tumor depth, perineural invasion, primary site, and degree of differentiation as well as bone invasion. Although widely used, the AJCC 7 staging system has been criticized for low specificity and for being too complicated for use in clinical practice.10 Other staging systems have been introduced by Breuninger and coworkers (hereinafter, Breuninger system),8 primarily based on clinical tumor size and histological tumor thickness, and by a research group at the Brigham and Women’s Hospital (BHW),9 with 4 risk features defining the risk categories. Recently, an 8th edition of the AJCC staging system, to be used for cSCCs in the head-and-neck area only, has been introduced and will be implemented in 2018.7